|
glaucoma |
46 |
|
humans |
46 |
|
intraocular pressure |
36 |
|
diabetic retinopathy |
35 |
|
male |
35 |
|
adult |
32 |
|
female |
31 |
|
retina |
27 |
|
animals |
25 |
|
cataract |
23 |
|
neuroprotection |
23 |
|
prevalence |
22 |
|
age-related macular degeneration |
21 |
|
epidemiology |
21 |
|
aged |
20 |
|
cornea |
20 |
|
myopia |
20 |
|
middle aged |
19 |
|
risk factors |
19 |
|
hong kong |
18 |
|
octa |
18 |
|
optical coherence tomography |
18 |
|
chinese |
16 |
|
phacoemulsification |
16 |
|
aged, 80 and over |
15 |
|
visual acuity |
14 |
|
visual impairment |
14 |
|
conjunctiva - virology |
13 |
|
optical coherence tomography angiography |
13 |
|
quality of life |
13 |
|
bronchi - cytology |
12 |
|
eye diseases |
12 |
|
influenza a virus, h1n1 subtype - metabolism |
12 |
|
influenza, human - virology |
12 |
|
meta-analysis |
12 |
|
normal tension glaucoma |
12 |
|
ocular surface disease |
12 |
|
photodynamic therapy |
12 |
|
ranibizumab |
12 |
|
respiratory system - virology |
12 |
|
retinal detachment |
12 |
|
silicone oil |
12 |
|
stroke |
12 |
|
systematic review |
12 |
|
china |
11 |
|
cross-sectional studies |
11 |
|
emulsification |
11 |
|
exophthalmometry values |
11 |
|
hertel's |
11 |
|
macular degeneration |
11 |
|
macular vascular density |
11 |
|
macular vessel density |
11 |
|
proptosis |
11 |
|
retinal ganglion cell |
11 |
|
selective laser trabeculoplasty |
11 |
|
swine |
11 |
|
treatment outcome |
11 |
|
vitrectomy |
11 |
|
acute disease |
10 |
|
adolescent |
10 |
|
apoptosis |
10 |
|
asians |
10 |
|
cataract extraction |
10 |
|
cataract surgery |
10 |
|
child |
10 |
|
conjunctiva |
10 |
|
covid-19 |
10 |
|
dry eye |
10 |
|
influenza a virus, h1n1 subtype - genetics - growth & development - pathogenicity |
10 |
|
influenza a virus, h1n2 subtype - genetics - growth & development - pathogenicity |
10 |
|
medication |
10 |
|
neurodegeneration |
10 |
|
organ culture techniques |
10 |
|
reassortant viruses - isolation & purification |
10 |
|
respiratory mucosa - virology |
10 |
|
viral tropism |
10 |
|
virulence |
10 |
|
angiogenesis |
9 |
|
anti-vegf |
9 |
|
diabetes mellitus |
9 |
|
inflammation |
9 |
|
mental health |
9 |
|
oxidative stress |
9 |
|
proliferative diabetic retinopathy |
9 |
|
prospective studies |
9 |
|
retinal degeneration |
9 |
|
screening |
9 |
|
surgery |
9 |
|
visual acuity - physiology |
9 |
|
vitreoretinal surgery |
9 |
|
young adult |
9 |
|
2009 pandemic h1n1 influenza virus |
8 |
|
collagen cross-linking |
8 |
|
deep learning |
8 |
|
endothelin-1 |
8 |
|
follow-up studies |
8 |
|
genetic variants |
8 |
|
genome-wide association studies |
8 |
|
hong kong - epidemiology |
8 |
|
imaging |
8 |
|
innate host responses |
8 |
|
insr |
8 |
|
lycium barbarum polysaccharides |
8 |
|
medical sciences |
8 |
|
obesity |
8 |
|
ophthalmology |
8 |
|
optic neuritis |
8 |
|
pterygium |
8 |
|
refraction, ocular - physiology |
8 |
|
severe cutaneous adverse reactions |
8 |
|
sight-threatening diabetic retinopathy |
8 |
|
stevens–johnson syndrome |
8 |
|
swine influenza virus |
8 |
|
tomography, optical coherence |
8 |
|
toxic epidermal necrolysis |
8 |
|
tropism |
8 |
|
animal model |
7 |
|
anti-inflammatory |
7 |
|
blindness |
7 |
|
cell death |
7 |
|
child, preschool |
7 |
|
complications |
7 |
|
cytokines |
7 |
|
diabetes |
7 |
|
dry eye disease |
7 |
|
eyelids |
7 |
|
infant |
7 |
|
ischemic stroke |
7 |
|
macular microcirculation |
7 |
|
meibomian gland dysfunction |
7 |
|
molecular sequence data |
7 |
|
ocular perfusion |
7 |
|
paediatric ophthalmology |
7 |
|
physical exercise |
7 |
|
refractive error |
7 |
|
reproducibility of results |
7 |
|
retinal ganglion cells - pathology |
7 |
|
safety |
7 |
|
success |
7 |
|
verteporfin |
7 |
|
vessel density |
7 |
|
visual field |
7 |
|
visual function |
7 |
|
acute ocular hypertensive injury |
6 |
|
amphiphilic |
6 |
|
asian continental ancestry group |
6 |
|
bacterial typing techniques |
6 |
|
bevacizumab |
6 |
|
bleb leak |
6 |
|
carotenoids |
6 |
|
cellular neuroscience |
6 |
|
chemicals and cas registry numbers |
6 |
|
corneal biomechanics |
6 |
|
cystic bleb |
6 |
|
endothelial cell count |
6 |
|
eye |
6 |
|
eye‐on‐a‐chip |
6 |
|
half-dose |
6 |
|
half-fluence |
6 |
|
hippocampus |
6 |
|
hypoxia |
6 |
|
incidence |
6 |
|
infectious keratitis |
6 |
|
keratitis - microbiology |
6 |
|
keratoconus |
6 |
|
mice |
6 |
|
microvascular complications |
6 |
|
molecular neuroscience |
6 |
|
nanoindentation |
6 |
|
neovascularization |
6 |
|
neuroscience |
6 |
|
pandemic |
6 |
|
polypoidal choroidal vasculopathy |
6 |
|
public health |
6 |
|
retinopathy of prematurity |
6 |
|
retrospective studies |
6 |
|
rna, ribosomal, 16s - genetics |
6 |
|
sequence analysis, dna |
6 |
|
spherical equivalent |
6 |
|
tamponade |
6 |
|
tomography |
6 |
|
trabeculectomy |
6 |
|
transcorneal electrical stimulation |
6 |
|
treatment |
6 |
|
visually impaired persons - statistics & numerical data |
6 |
|
3d culturing |
5 |
|
actinomycetales - isolation & purification |
5 |
|
actinomycetales infections - diagnosis - microbiology |
5 |
|
aerosolization |
5 |
|
aerosols |
5 |
|
age related macular degeneration |
5 |
|
arthritis, infectious - microbiology |
5 |
|
asia |
5 |
|
astrocyte |
5 |
|
astrocytes |
5 |
|
autoimmune encephalitis |
5 |
|
awareness |
5 |
|
bacteremia - complications - microbiology |
5 |
|
biometry |
5 |
|
blood-brain barrier |
5 |
|
blood-retinal barrier |
5 |
|
brain injury |
5 |
|
cardiac dysfunction |
5 |
|
cardiac function reserve |
5 |
|
cellulitis - microbiology |
5 |
|
childhood glaucoma |
5 |
|
collagen crosslinking |
5 |
|
composite hydrogel |
5 |
|
conjunctival leak |
5 |
|
cost-effectiveness |
5 |
|
covid |
5 |
|
cyclodiode |
5 |
|
cytomegalovirus retinitis |
5 |
|
diabetic cardiomyopathy |
5 |
|
disease progression |
5 |
|
dna, bacterial |
5 |
|
dna, bacterial - chemistry - genetics |
5 |
|
dna, ribosomal |
5 |
|
dna, ribosomal - chemistry - genetics |
5 |
|
down syndrome - epidemiology |
5 |
|
drop instillation |
5 |
|
droplets |
5 |
|
dry eye syndrome |
5 |
|
early identification |
5 |
|
encapsulated-cell therapy |
5 |
|
endophthalmitis |
5 |
|
exercise echocardiography |
5 |
|
eye diseases - epidemiology |
5 |
|
fibroblasts |
5 |
|
filtering surgery |
5 |
|
fishes - microbiology |
5 |
|
gene deletion |
5 |
|
glia |
5 |
|
gout - microbiology |
5 |
|
health preference |
5 |
|
health-related quality of life |
5 |
|
heart disease |
5 |
|
hemolysis |
5 |
|
high‐molecular‐weight additive |
5 |
|
infections |
5 |
|
intraocular lens |
5 |
|
ischemia |
5 |
|
knowledge |
5 |
|
laser |
5 |
|
laser therapy |
5 |
|
lens implantation, intraocular |
5 |
|
lenses, intraocular |
5 |
|
limbic encephalitis |
5 |
|
lycium barbarum |
5 |
|
menorrhagia |
5 |
|
mental disorders - epidemiology |
5 |
|
mice, inbred c57bl |
5 |
|
mitochondria |
5 |
|
myofibroblasts |
5 |
|
north america |
5 |
|
ocular disease |
5 |
|
ocular surface disease index |
5 |
|
open-angle glaucoma |
5 |
|
optic nerve head |
5 |
|
optical coherence |
5 |
|
optical coherence tomography (oct) |
5 |
|
paraneoplastic syndrome |
5 |
|
patients |
5 |
|
phylogeny |
5 |
|
polysaccharides, bacterial - biosynthesis |
5 |
|
polyunsaturated fatty acid |
5 |
|
postoperative complications |
5 |
|
precision eye healthcare |
5 |
|
primary angle-closure glaucoma |
5 |
|
primary open-angle glaucoma |
5 |
|
questionnaires |
5 |
|
refractive surgery |
5 |
|
reperfusion injury |
5 |
|
retinoblastoma |
5 |
|
rheumatoid arthritis |
5 |
|
riboflavin |
5 |
|
saturated fatty acid |
5 |
|
severity of illness index |
5 |
|
sjogren syndrome |
5 |
|
stevens-johnson syndrome |
5 |
|
streptococcal infections - microbiology |
5 |
|
streptococcus - classification - isolation & purification - pathogenicity - physiology |
5 |
|
streptococcus iniae |
5 |
|
stromal fibrosis |
5 |
|
survey |
5 |
|
tear osmolarity |
5 |
|
thyroid eye disease |
5 |
|
transforming growth factor-beta 1 |
5 |
|
vascular factors |
5 |
|
viscosity |
5 |
|
vision |
5 |
|
vitreous substitutes |
5 |
|
*locomotion |
4 |
|
24-hour |
4 |
|
426 apoptosis/cell death |
4 |
|
530 ganglion cells |
4 |
|
685 retina |
4 |
|
accelerated crosslinking |
4 |
|
activities of daily living/*classification |
4 |
|
aldehyde reductase - antagonists & inhibitors - deficiency - genetics - physiology |
4 |
|
aldehyde reductase - deficiency - genetics |
4 |
|
aldehyde reductase - deficiency - genetics - metabolism |
4 |
|
alginate |
4 |
|
alginates - pharmacology |
4 |
|
alzheimer's disease |
4 |
|
amyloidosis |
4 |
|
analysis of variance |
4 |
|
angle-closure |
4 |
|
animals, newborn - metabolism |
4 |
|
antigens, cd31 - genetics |
4 |
|
apoptosis - drug effects |
4 |
|
apoptosis - physiology |
4 |
|
argon laser peripheral iridoplasty |
4 |
|
astigmatism |
4 |
|
astrocytes - metabolism |
4 |
|
atropine |
4 |
|
blood pressure - physiology |
4 |
|
blood-brain barrier - drug effects |
4 |
|
blood-retinal barrier - drug effects - physiopathology |
4 |
|
blood-retinal barrier - physiopathology |
4 |
|
blotting, western |
4 |
|
brain - cytology - metabolism |
4 |
|
brain chemistry |
4 |
|
brain chemistry - genetics - physiology |
4 |
|
brain edema - etiology - pathology - physiopathology - prevention and control |
4 |
|
brain ischemia - enzymology - metabolism - pathology |
4 |
|
brain slice |
4 |
|
cataract - complications |
4 |
|
cataract extraction - methods |
4 |
|
cell death - physiology |
4 |
|
cell division |
4 |
|
cell encapsulation |
4 |
|
cell proliferation |
4 |
|
cell survival |
4 |
|
central cornea thickness |
4 |
|
central corneal thickness |
4 |
|
cerebral infarct |
4 |
|
cerebral ischemia |
4 |
|
cerebral palsy/*diagnosis/epidemiology/rehabilitation |
4 |
|
child health (paediatrics) |
4 |
|
choroid diseases - diagnosis |
4 |
|
choroidal neovascularization |
4 |
|
choroidal thickness |
4 |
|
classification |
4 |
|
collagen |
4 |
|
collagen - pharmacology |
4 |
|
collagen–alginate composite hydrogel |
4 |
|
consensual ophthalmotonic reaction |
4 |
|
corneal collagen crosslinking |
4 |
|
corneal resurfacing |
4 |
|
corneal scarring |
4 |
|
corneal wound healing |
4 |
|
cortex |
4 |
|
corvis st |
4 |
|
coulter counter |
4 |
|
db/db mouse |
4 |
|
diabetes mellitus - genetics - physiopathology |
4 |
|
diabetes mellitus, type 2 - complications - enzymology - metabolism - pathology |
4 |
|
diabetic macular edema |
4 |
|
direct ophthalmoscopy |
4 |
|
disability evaluation |
4 |
|
disease models, animal |
4 |
|
disease progress monitoring |
4 |
|
drug carriers |
4 |
|
drugs, chinese herbal - pharmacology |
4 |
|
drugs, chinese herbal - pharmacology - therapeutic use |
4 |
|
edema |
4 |
|
electrical phosphene threshold |
4 |
|
electrical stimulation |
4 |
|
electroretinography |
4 |
|
encapsulated cell therapy |
4 |
|
endothelin-1 - biosynthesis - genetics |
4 |
|
endothelium, vascular - cytology - metabolism |
4 |
|
ex-press |
4 |
|
express shunt |
4 |
|
eye disease |
4 |
|
eye diseases - diagnosis |
4 |
|
eye disorders |
4 |
|
eye-on-a-chip |
4 |
|
fibroblast |
4 |
|
g-probe |
4 |
|
gdnf |
4 |
|
gene expression regulation, enzymologic |
4 |
|
genetic association |
4 |
|
glaucoma surgery |
4 |
|
glaucoma, angle-closure |
4 |
|
glial cell |
4 |
|
glial cell line-derived neurotrophic factor - secretion |
4 |
|
glutamic acid - metabolism |
4 |
|
handheld device |
4 |
|
health services |
4 |
|
hek293 cells |
4 |
|
human keratocytes |
4 |
|
hydrogel |
4 |
|
hyperopia |
4 |
|
hypoxia-ischemia, brain - metabolism |
4 |
|
imidazolidines - therapeutic use |
4 |
|
immunohistochemistry |
4 |
|
l-iditol 2-dehydrogenase - antagonists & inhibitors - genetics - physiology |
4 |
|
laser coagulation - methods |
4 |
|
laser light scattering |
4 |
|
machine learning |
4 |
|
macula |
4 |
|
magnetic resonance imaging |
4 |
|
measurement |
4 |
|
medical education |
4 |
|
meibography |
4 |
|
mental retardation/*diagnosis/epidemiology |
4 |
|
mice, mutant strains |
4 |
|
microencapsulation |
4 |
|
microglia |
4 |
|
microsphere |
4 |
|
microspheres |
4 |
|
monitoring system |
4 |
|
mouse |
4 |
|
müller cells |
4 |
|
nerve fibers |
4 |
|
neuroglia |
4 |
|
neuroglia - metabolism |
4 |
|
neurologic examination/*statistics & numerical data |
4 |
|
neuronal apoptosis |
4 |
|
neurons - drug effects - pathology |
4 |
|
neuroprotective agents - pharmacology |
4 |
|
nfκb |
4 |
|
oct |
4 |
|
ocular redness |
4 |
|
open angle glaucoma |
4 |
|
operative |
4 |
|
ophthalmology and optometry |
4 |
|
optic nerve |
4 |
|
oxidative stress - drug effects |
4 |
|
papilledema - enzymology - pathology - prevention & control |
4 |
|
phacoemulsification - methods |
4 |
|
phacotrabeculectomy |
4 |
|
pilot projects |
4 |
|
polymerase chain reaction |
4 |
|
postoperative complications - prevention & control |
4 |
|
pregnancy |
4 |
|
prevention |
4 |
|
progressive outer retinal necrosis |
4 |
|
pyrimidines - therapeutic use |
4 |
|
rap1 |
4 |
|
rat |
4 |
|
reconstruction |
4 |
|
recurrence |
4 |
|
regeneration |
4 |
|
renal transplantation |
4 |
|
reoperation |
4 |
|
reperfusion |
4 |
|
reperfusion injury - drug therapy |
4 |
|
reperfusion injury - enzymology - pathology - prevention & control |
4 |
|
retina - cytology - enzymology |
4 |
|
retina - pathology |
4 |
|
retinal diseases |
4 |
|
retinal diseases - enzymology - metabolism - pathology |
4 |
|
retinal diseases - enzymology - pathology - prevention & control |
4 |
|
retinal nerve fiber layer |
4 |
|
retinitis pigmentosa |
4 |
|
rna, messenger - biosynthesis |
4 |
|
selective laser trabeculplasty |
4 |
|
self care/classification/*statistics & numerical data |
4 |
|
silicone oils - administration and dosage - chemistry |
4 |
|
sorbitol dehydrogenase |
4 |
|
spectral reconstruction |
4 |
|
statistics as topic |
4 |
|
stroke - complications - drug therapy - pathology - physiopathology |
4 |
|
stroke - enzymology - metabolism - pathology |
4 |
|
subconjunctival hemorrhage |
4 |
|
surgical procedures |
4 |
|
tgfβ1 |
4 |
|
trans-epithelial crosslinking |
4 |
|
transgenic mice |
4 |
|
treatment other |
4 |
|
treatment surgery |
4 |
|
trends |
4 |
|
uveitis |
4 |
|
varicella zoster virus |
4 |
|
vascular endothelial growth factor |
4 |
|
vascular endothelial growth factor a - genetics |
4 |
|
vision rehabilitation |
4 |
|
xanthophyll |
4 |
|
412 age-related macular degeneration |
3 |
|
416 amacrine cells |
3 |
|
571 ischemia |
3 |
|
594 microglia |
3 |
|
602 muller cells |
3 |
|
606 neovascularization |
3 |
|
612 neuroprotection |
3 |
|
651 proliferation |
3 |
|
652 proliferative vitreoretinopathy |
3 |
|
696 retinal glia |
3 |
|
697 retinal neovascularization |
3 |
|
698 retinal pigment epithelium |
3 |
|
703 retinopathy of prematurity |
3 |
|
737 transplantation |
3 |
|
762 vitreoretinal surgery |
3 |
|
764 vitreous substitutes |
3 |
|
accuracy |
3 |
|
adhd |
3 |
|
administration, oral |
3 |
|
age |
3 |
|
ahmed glaucoma valve |
3 |
|
aldehyde reductase - antagonists & inhibitors - genetics - metabolism |
3 |
|
aldehyde reductase - deficiency |
3 |
|
aldose reductase |
3 |
|
algorithms |
3 |
|
analgesia |
3 |
|
angle |
3 |
|
animal models |
3 |
|
animals, newborn |
3 |
|
anterior chamber depth |
3 |
|
anterior segment oct |
3 |
|
antibacterial |
3 |
|
antiglaucoma medication |
3 |
|
antioxidant |
3 |
|
antioxidant (2.084) |
3 |
|
antioxidants - pharmacology |
3 |
|
aquaporin |
3 |
|
aquaporin 4 |
3 |
|
aquaporin 4 - genetics - metabolism |
3 |
|
aquaporins - biosynthesis |
3 |
|
artificial intelligence |
3 |
|
astrocytes - drug effects - physiology |
3 |
|
astrocytes - metabolism - ultrastructure |
3 |
|
attention-deficit hyperactivity disorder |
3 |
|
attention-deficit/hyperactivity disorder |
3 |
|
autoimmune diseases |
3 |
|
autoimmune disorders |
3 |
|
autophagy inhibitors |
3 |
|
axial length |
3 |
|
baclofen |
3 |
|
behavior, animal - physiology |
3 |
|
best corrected visual acuity |
3 |
|
beta-galactosidase - analysis |
3 |
|
biomaterials |
3 |
|
biosafety |
3 |
|
blood-brain barrier - physiology |
3 |
|
blood–brain barrier |
3 |
|
blotting, northern - methods |
3 |
|
brain - blood supply - cytology - metabolism - pathology |
3 |
|
brain - blood supply - pathology |
3 |
|
brain - pathology |
3 |
|
brain damage |
3 |
|
brain development |
3 |
|
brain edema - chemically induced - physiopathology |
3 |
|
brain edema - etiology - metabolism |
3 |
|
brain injuries - metabolism - pathology - prevention & control |
3 |
|
brain ischemia - metabolism - pathology - prevention & control |
3 |
|
bullous keratopathy |
3 |
|
cancer treatment |
3 |
|
capillaries - physiology |
3 |
|
carotenoid |
3 |
|
case-control studies |
3 |
|
caspase |
3 |
|
caspase 3 - metabolism |
3 |
|
cataract - epidemiology |
3 |
|
cell damage |
3 |
|
cell death and survival |
3 |
|
cell hypoxia |
3 |
|
cell size |
3 |
|
cell therapy |
3 |
|
cells, cultured |
3 |
|
central serous chorioretinopathy |
3 |
|
childhood myopia |
3 |
|
children |
3 |
|
chinese population |
3 |
|
choroidal neovascularization - diagnosis - drug therapy - microbiology |
3 |
|
ciliochoroidal detachment |
3 |
|
clinical applications |
3 |
|
clinical article |
3 |
|
clinical practice |
3 |
|
clinical trial |
3 |
|
clinical trial (2.172) |
3 |
|
clinical trials as topic |
3 |
|
cohort studies |
3 |
|
coloring agents |
3 |
|
combination therapy |
3 |
|
combined modality therapy |
3 |
|
conditional |
3 |
|
confocal scanning laser ophthalmoscopy |
3 |
|
controlled study |
3 |
|
conventional glycemic control |
3 |
|
cornea stromal scarring |
3 |
|
corneal decompensation |
3 |
|
corneal donation |
3 |
|
corneal edema |
3 |
|
corneal melting |
3 |
|
corneal thickness |
3 |
|
coronavirus |
3 |
|
covid-19 pandemic |
3 |
|
crosslinking |
3 |
|
crystallization |
3 |
|
culture media, serum-free |
3 |
|
cytoprotection - physiology |
3 |
|
cytotoxic edema |
3 |
|
dark agouti rats |
3 |
|
degeneration |
3 |
|
demyelinating disease |
3 |
|
determinants |
3 |
|
diagnosis |
3 |
|
diagnostic techniques, ophthalmological |
3 |
|
diet supplementation |
3 |
|
dietary supplement |
3 |
|
dimethylpolysiloxanes - chemistry |
3 |
|
diseases |
3 |
|
diurnal intraocular pressure fluctuation |
3 |
|
donor cells |
3 |
|
double emulsion |
3 |
|
doxycycline |
3 |
|
drainage - methods |
3 |
|
droplet microfluidics |
3 |
|
drusen |
3 |
|
east respiratory |
3 |
|
ef1α |
3 |
|
eiia-cre |
3 |
|
electrical stimulation (es) |
3 |
|
electrical stimulation therapy |
3 |
|
electroretinographic responses |
3 |
|
electroretinography: non-clinical |
3 |
|
embryo, mammalian |
3 |
|
emulsions |
3 |
|
encapsulation |
3 |
|
endogenous endophthalmitis |
3 |
|
endophthalmitis - diagnosis - drug therapy - microbiology |
3 |
|
endotamponade |
3 |
|
endothelin receptor antagonist |
3 |
|
endothelin receptors |
3 |
|
endothelin-1 - biosynthesis |
3 |
|
endothelin-1 - genetics - metabolism |
3 |
|
endothelin-1 - genetics - metabolism - pharmacology |
3 |
|
endothelin-2 - genetics - metabolism |
3 |
|
endothelin-3 |
3 |
|
endothelin-3 - genetics - metabolism |
3 |
|
endothelium |
3 |
|
endothelium, vascular - metabolism - pathology |
3 |
|
enhanced depth imaging optical coherence tomography |
3 |
|
enzyme-linked immunosorbent assay |
3 |
|
epithelial wound healing |
3 |
|
epithelial-mesenchymal transition |
3 |
|
epithelium |
3 |
|
et-1-deficient mice |
3 |
|
evans blue |
3 |
|
experimental therapy |
3 |
|
experimental – laboratory |
3 |
|
express mini-shunt |
3 |
|
eye hemorrhage |
3 |
|
eye infections, bacterial - diagnosis - drug therapy - microbiology |
3 |
|
eye infections, viral - diagnosis - immunology - therapy |
3 |
|
eye movements |
3 |
|
failure |
3 |
|
filtering bleb |
3 |
|
fludarabine |
3 |
|
free radical |
3 |
|
ganciclovir |
3 |
|
gene expression regulation |
3 |
|
gene expression regulation, developmental - physiology |
3 |
|
gene mutation |
3 |
|
genes, reporter - genetics |
3 |
|
genetics |
3 |
|
genotype |
3 |
|
gfap |
3 |
|
glands |
3 |
|
glaucoma drainage devices |
3 |
|
glaucoma implants |
3 |
|
glaucoma, angle-closure - surgery |
3 |
|
glial fibrillary acidic protein - genetics - metabolism |
3 |
|
glucose control |
3 |
|
goniotomy |
3 |
|
graves’ disease |
3 |
|
head and neck neoplasms/*surgery |
3 |
|
healon |
3 |
|
heavy silicone oil |
3 |
|
hek cells |
3 |
|
hematopoietic stem cell transplantation - adverse effects |
3 |
|
herpes simplex keratitis |
3 |
|
herpes zoster ophthalmicus - diagnosis - immunology - therapy |
3 |
|
hippocampus - blood supply - pathology |
3 |
|
home inspection |
3 |
|
homeostasis |
3 |
|
hydrophobic acrylic |
3 |
|
hypercholesterolemia |
3 |
|
hypoxia/ischemia |
3 |
|
image processing, computer-assisted |
3 |
|
imaging methods (ct, fa, icg, mri, oct, rta, slo, ultrasound) |
3 |
|
imidazolidines - metabolism |
3 |
|
immune checkpoint inhibitors |
3 |
|
immune homeostasis |
3 |
|
immune-related adverse events |
3 |
|
immunity |
3 |
|
immunocompromised host |
3 |
|
immunosuppression - adverse effects |
3 |
|
in situ hybridization |
3 |
|
in situ hybridization - methods |
3 |
|
in-jury |
3 |
|
infant, newborn |
3 |
|
infarct |
3 |
|
infarction, middle cerebral artery |
3 |
|
infarction, middle cerebral artery - complications - metabolism - pathology |
3 |
|
infarction, middle cerebral artery - genetics - metabolism - pathology |
3 |
|
infection |
3 |
|
inflammatory eye disease |
3 |
|
inflammatory pain |
3 |
|
insulin dependent diabetes mellitus |
3 |
|
integrases - genetics - metabolism |
3 |
|
intense glycemic control |
3 |
|
internal tamponades |
3 |
|
intestinal microbiota |
3 |
|
intraocular pressure - drug effects |
3 |
|
intraocular pressure - physiology |
3 |
|
intraocular pressure/*physiology |
3 |
|
intravitreal |
3 |
|
iris |
3 |
|
iris - surgery |
3 |
|
iron - metabolism |
3 |
|
isoprostanes |
3 |
|
jugular veins/*surgery |
3 |
|
klebsiella infections - diagnosis - drug therapy - microbiology |
3 |
|
knockout mice |
3 |
|
l-iditol 2-dehydrogenase - genetics - metabolism |
3 |
|
l-lactate dehydrogenase - secretion |
3 |
|
lactate dehydrogenase |
3 |
|
lamp1 |
3 |
|
lasik |
3 |
|
lc3 |
3 |
|
lens |
3 |
|
lens and zonules |
3 |
|
leukemia, myeloid, acute - therapy |
3 |
|
light-triggered drug release |
3 |
|
lipid peroxidation |
3 |
|
lipid, atherosclerosis |
3 |
|
liver abscess - diagnosis - drug therapy - microbiology |
3 |
|
lutein |
3 |
|
macroautophagy |
3 |
|
management |
3 |
|
mcao |
3 |
|
medicine & public health |
3 |
|
medulla oblongata - embryology - metabolism |
3 |
|
melatonin |
3 |
|
mendelian analysis |
3 |
|
method of cell delivery |
3 |
|
mice, inbred cba |
3 |
|
mice, knockout |
3 |
|
mice, transgenic |
3 |
|
microbead occlusion |
3 |
|
middle east |
3 |
|
minimization |
3 |
|
models, anatomic |
3 |
|
models, biological |
3 |
|
monitoring |
3 |
|
mouse embryo |
3 |
|
mycoses - drug therapy |
3 |
|
myelination |
3 |
|
myopia progression control |
3 |
|
n-methyl-d-aspartate receptors |
3 |
|
nanotechnology |
3 |
|
natural product |
3 |
|
nd:yag laser |
3 |
|
neck dissection/*methods |
3 |
|
necrosis |
3 |
|
nerve degeneration - genetics - metabolism - pathology |
3 |
|
nerve fibers - pathology |
3 |
|
nerve fibers/*pathology |
3 |
|
nervous system diseases - etiology |
3 |
|
neurodevelopmental disorder |
3 |
|
neurogenesis |
3 |
|
neurologic deficit |
3 |
|
neurological deficit |
3 |
|
neuroophthalmology |
3 |
|
neuroplasticity |
3 |
|
neuroprotective agents |
3 |
|
neurotrauma |
3 |
|
non insulin dependent diabetes mellitus |
3 |
|
ocular disorders |
3 |
|
ocular drug delivery |
3 |
|
ocular hypertension |
3 |
|
ocular hypertension/etiology |
3 |
|
ocular stress |
3 |
|
ocular surface diseases |
3 |
|
oligodendrocyte |
3 |
|
omega-6/omega-3 polyunsaturated fatty acid ratio |
3 |
|
ophthalmic considerations |
3 |
|
ophthalmic diseases |
3 |
|
ophthalmic specialty clinics |
3 |
|
opportunistic infections - diagnosis - immunology - therapy |
3 |
|
optic disk - anatomy & histology |
3 |
|
optic disk/*pathology |
3 |
|
optics and refraction |
3 |
|
outcome |
3 |
|
oxygen-induced retinopathy |
3 |
|
pediatric glaucoma |
3 |
|
pediatric glaucoma surgery |
3 |
|
peptide elongation factor 1 - genetics |
3 |
|
perfluorobutylpentane (f4h5) |
3 |
|
perfluorocarbon liquid |
3 |
|
perfluoropropane |
3 |
|
phacomorphic |
3 |
|
phacomorphic glaucoma |
3 |
|
phenotype |
3 |
|
photoreceptor |
3 |
|
photoreceptor cells, vertebrate - pathology |
3 |
|
physical activity |
3 |
|
placo analysis |
3 |
|
plateau iris configuration |
3 |
|
plateau iris syndrome |
3 |
|
polyol pathway |
3 |
|
pons - embryology - metabolism |
3 |
|
population-based study |
3 |
|
posterior chamber |
3 |
|
postoperative period |
3 |
|
potential risks |
3 |
|
pre-emptive |
3 |
|
predictors |
3 |
|
primary acute angle closure |
3 |
|
primary congenital glaucoma |
3 |
|
prognosis |
3 |
|
programmed cell death |
3 |
|
propofol |
3 |
|
public health care system |
3 |
|
quantitative collection |
3 |
|
rcts |
3 |
|
rd10 |
3 |
|
receptor, endothelin a - antagonists & inhibitors |
3 |
|
receptor, endothelin b - antagonists & inhibitors |
3 |
|
receptors, endothelin - genetics - metabolism |
3 |
|
receptors, transferrin - metabolism |
3 |
|
recurrent acute angle-closure attack |
3 |
|
regulated cell death |
3 |
|
reperfusion injury - metabolism - pathology |
3 |
|
reperfusion injury - metabolism - pathology - prevention and control |
3 |
|
research design |
3 |
|
respiratory control |
3 |
|
retinal degenerative diseases |
3 |
|
retinal detachment - pathology |
3 |
|
retinal detachment - surgery |
3 |
|
retinal diseases - etiology |
3 |
|
retinal diseases - metabolism - pathology - prevention and control |
3 |
|
retinal diseases - surgery |
3 |
|
retinal ganglion cells |
3 |
|
retinal ganglion cells - cytology |
3 |
|
retinal ganglion cells - drug effects - pathology |
3 |
|
retinal necrosis syndrome, acute - diagnosis - immunology - therapy |
3 |
|
retinal neovascularization - enzymology - pathology - prevention and control |
3 |
|
retinal nerve fiber thickness |
3 |
|
retinal nerve fibre layer |
3 |
|
retinal neuron |
3 |
|
retinal neurons |
3 |
|
retinal thickness |
3 |
|
retinopathy |
3 |
|
retinopathy of prematurity - enzymology - pathology - prevention and control |
3 |
|
reverse transcriptase polymerase chain reaction |
3 |
|
risk factor |
3 |
|
rituximab |
3 |
|
rna, messenger - analysis |
3 |
|
rna, messenger - metabolism |
3 |
|
rnfl |
3 |
|
rubeotic glaucoma |
3 |
|
saccades - physiology |
3 |
|
scanning laser polarimetry |
3 |
|
scleral buckling |
3 |
|
self-assembly |
3 |
|
sensitivity and specificity |
3 |
|
silicone oils - adverse effects |
3 |
|
silicone oils - chemistry |
3 |
|
single cell |
3 |
|
slt |
3 |
|
smile |
3 |
|
spectral domain optical coherence tomography |
3 |
|
specular microscopy |
3 |
|
stem cell |
3 |
|
stem cell therapy |
3 |
|
steroid-induced glaucoma |
3 |
|
success rate |
3 |
|
sulfur hexafluoride |
3 |
|
surgical procedures, minimally invasive |
3 |
|
sustained drug delivery |
3 |
|
syndrome |
3 |
|
systemic treatment |
3 |
|
target cell types |
3 |
|
testis - blood supply - metabolism - ultrastructure |
3 |
|
therapy |
3 |
|
time factors |
3 |
|
tissue regeneration |
3 |
|
tomography, x-ray computed |
3 |
|
tonometry, ocular/methods |
3 |
|
topical treatment |
3 |
|
trabeculectomy - methods |
3 |
|
trabeculotomy |
3 |
|
traditional chinese medicine (2.592) |
3 |
|
traditional chinese medicine (tcm) |
3 |
|
transferrin - metabolism |
3 |
|
trauma |
3 |
|
treatment lasers |
3 |
|
triage |
3 |
|
triamcinolone acetonide |
3 |
|
trigonal small molecules |
3 |
|
true exfoliation |
3 |
|
tube shunts |
3 |
|
two-tiered |
3 |
|
tyrosine - analogs & derivatives - metabolism |
3 |
|
uk biobank |
3 |
|
ulcer |
3 |
|
up-regulation |
3 |
|
uveitic glaucoma |
3 |
|
vasopressin receptor antagonist |
3 |
|
ventrolateral medulla |
3 |
|
vessel |
3 |
|
viral proteins - genetics - metabolism |
3 |
|
vision disorders |
3 |
|
visual cortex |
3 |
|
visual outcome |
3 |
|
vitreous body - surgery |
3 |
|
water - metabolism |
3 |
|
water intoxication |
3 |
|
0.01% atropine |
2 |
|
3d bioprinting |
2 |
|
3d rnfl profile |
2 |
|
3d-migrated |
2 |
|
481 cornea |
2 |
|
abscess - diagnosis - microbiology - surgery |
2 |
|
acetazolamide - administration and dosage |
2 |
|
acetazolamide - therapeutic use |
2 |
|
acute angle-closure glaucoma |
2 |
|
acute glaucoma |
2 |
|
acute phacomorphic angle-closure |
2 |
|
acute primary angle closure |
2 |
|
acute primary angle-closure |
2 |
|
administration, topical |
2 |
|
adolescent health |
2 |
|
aflibercept |
2 |
|
age correlation |
2 |
|
age-related macular diseases |
2 |
|
age-related neurodegeneration |
2 |
|
all-aqueous droplets |
2 |
|
all-aqueous system |
2 |
|
amblyopia |
2 |
|
amino acid sequence |
2 |
|
anesthesia, local - methods |
2 |
|
angiography |
2 |
|
angle closure glaucoma |
2 |
|
angle-closure glaucoma |
2 |
|
anterior chamber - anatomy & histology - surgery |
2 |
|
anterior chamber - anatomy & histology - ultrasonography |
2 |
|
anterior chamber - metabolism - pathology |
2 |
|
anterior chamber angle |
2 |
|
anterior segment optical coherence tomography |
2 |
|
anthropometry |
2 |
|
anti-allergic agents |
2 |
|
anti-bacterial agents - administration & dosage |
2 |
|
anti-inflammatory agents - therapeutic use |
2 |
|
anticoagulants - administration & dosage - pharmacokinetics - therapeutic use |
2 |
|
anticonvulsants - adverse effects |
2 |
|
antidepressive agents - adverse effects |
2 |
|
antifungal agents - administration & dosage |
2 |
|
antihypertensive agents - administration & dosage |
2 |
|
antihypertensive agents - therapeutic use |
2 |
|
antineoplastic agents - administration & dosage - adverse effects - therapeutic use |
2 |
|
antivascular endothelial growth factor |
2 |
|
applications |
2 |
|
aqueous two-phase system |
2 |
|
arsenicals - administration & dosage - adverse effects - therapeutic use |
2 |
|
asian |
2 |
|
asian continental ancestry group - ethnology |
2 |
|
assembly |
2 |
|
autoimmunity |
2 |
|
axonal regeneration |
2 |
|
axons - pathology |
2 |
|
basement membrane - pathology - physiopathology - surgery |
2 |
|
bio-heterojunction |
2 |
|
bioactivity preservation |
2 |
|
biocompatibility |
2 |
|
biomechanical properties |
2 |
|
biomimetic |
2 |
|
biomolecular assembly |
2 |
|
birefringence |
2 |
|
blindness - chemically induced - therapy |
2 |
|
blindness prevention |
2 |
|
blood glucose |
2 |
|
body height |
2 |
|
both eyes |
2 |
|
botox |
2 |
|
botulinum toxin |
2 |
|
brain ischemia - chemically induced - drug therapy |
2 |
|
brilliant blue g |
2 |
|
brimonidine |
2 |
|
bronchiectasis |
2 |
|
bronchiectasis - diagnosis - microbiology - surgery |
2 |
|
bruch's membrane opening-minimum rim width |
2 |
|
calcitriol |
2 |
|
calcium |
2 |
|
calcium channel blockers |
2 |
|
cardiovascular health |
2 |
|
cataract - complications - therapy |
2 |
|
cataract barriers |
2 |
|
cataract extraction - adverse effects - statistics & numerical data |
2 |
|
cataract screening |
2 |
|
cattle |
2 |
|
cell count |
2 |
|
cell differentiation - physiology |
2 |
|
cell proliferation - drug effects |
2 |
|
central nervous system injury |
2 |